Abstract: Provided herein are compounds (e.g., compounds of Formula (I) and Formula (II), that modulate HCN channels, intermembrane proteins that serve as nonselective voltage-gated cation channels in the plasma membranes of heart and brain cells. Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HCN-related disorders (e.g., pain) with the compounds in a subject, by administering the compounds and/or compositions described herein.
Type:
Application
Filed:
June 27, 2019
Publication date:
September 2, 2021
Applicant:
Cornell University
Inventors:
Gareth R. Tibbs, Peter A. Goldstein, Anthony A. Sauve, Rajendra Uprety, James David Warren, Rebecca L. Joyce, Dipti N. Barman
Abstract: Compositions and pharmaceutical compositions including a dendrimer-resveratrol complex and methods for making and using the compositions are described herein. Methods of treating cancer, cardiovascular disease, cardiac failure, diabetes, Alzheimer's disease, Parkinson's disease and other brain diseases, fatty liver disease, obesity, cataracts, osteoporosis, muscle wasting, sleep disorders, acoustic trauma, inflammatory disease, psoriasis, arthritis, colitis, aging, viral disease, reproductive disease, and skin conditions or disorders including administering a therapeutically effective amount of the compositions to a subject in need are also provided. The compositions may be topically applied to skin or mucous membranes.
Type:
Application
Filed:
May 19, 2021
Publication date:
September 2, 2021
Inventors:
Abhay Singh Chauhan, Eric Andrew Newenhouse, Armin Henry Gerhardt
Abstract: The present disclosure relates to compositions for improving vision in a patient and methods of administering a composition to a patient, particularly in the form of a dietary supplement, which addresses vision impairment and promotes the health of a patient experiencing problems associated with deteriorated eyesight, including macular degeneration. The present disclosure also relates to methods for formulating the composition described herein.
Abstract: The present invention relates to a methyl-sulfonyl methane containing composition for preventing or alleviating obesity, fatty liver and diabetes. An MSM (methyl sulfonyl methane: dimethyl sulfone)-containing composition according to the present invention, which contains 75 to 85 wt. % of MSM, 0.5 to 2 wt. % of vitamin B6 hydrochloride, 0.01 to 1 wt. % of folic acid, 2 to 8 wt. % of galacto-oligosaccharide, 10 to 18 wt. % of rice-fermented magnesium, and 0.5 to 3 wt. % of vitamin C, not only can prevent and treat obesity by reducing the size of fat cells and inhibiting differentiation of mature fat cells, but also lowers triglyceride and the total cholesterol concentration in the liver, thus having a fatty liver preventing effect, and also reduces the concentration of insulin-like growth factor, thus also being effective for diabetes.
Abstract: Methods of making safe extracts of Curcuma are provided. The processes provided include methods that use an extraction solvent that is at least substantially non-toxic and useful also as a pharmaceutically acceptable carrier in liquid dosage forms. The processes can produce a significantly higher yield from a single extraction than the state-of-the-art processes. For example, liquid dosage forms can be produced directly from the extraction process without requiring removal of the extraction solvent, reducing complexity and cost of processing over the state-of-the-art. Methods of making microemulsions and nanoemulsions are also provided to enhance the bioavailability and stability of the extracts.
Abstract: This invention provides a composition comprising, as an active ingredient, a turmeric-derived ingredient, which is useful for treatment, prevention, or amelioration of Alzheimer's disease. This invention relates to a composition for treatment of Alzheimer's disease, a composition for suppression of brain nerve cell death, a composition for suppression of microglia activation induced by amyloid ? peptide, or a composition for suppression of PGE2, TNF-?, or IL-1? production induced by amyloid ? peptide comprising, as an active ingredient, a turmeric extract extracted with at least one extraction solvent selected from water and a hydrophilic organic solvent or at least one of termeronol A and termeronol B.
Abstract: Disclosed is a use of a liposomal pharmaceutical preparation of mitoxantrone in the preparation of a medicament for treating lymphoma, wherein the lymphoma is preferably non-Hodgkin's lymphoma, further preferably aggressive non-Hodgkin's lymphoma, more preferably diffuse large B-cell lymphoma or peripheral T-cell lymphoma, and more further preferably relapsed or refractory diffuse large B-cell lymphoma or peripheral T-cell lymphoma. The mitoxantrone liposomes are used as single anti-tumor therapeutic agent without being combined with other anti-tumor agents.
Abstract: Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT2B agonists such as norfenfluramine with known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of metabolite down thereby making the first drug safer.
Abstract: The present Invention relates to the use of choline butyrate or butyrylcholinc in food and in particular in the treatment of Intestinal disorders and in the stimulation of the brain development. Furthermore, the invention provides for a food supplement and a pharmaceutical composition comprising choline butyrate or butyrylcholine, The invention also relates to an animal feed comprising choline butyrate or butyrylcholinc or said food supplement.
Abstract: The present invention relates to a pharmaceutical combination for use in the treatment, prevention and/or stabilization of age-related diseases and/or degenerative diseases. In particular, said pharmaceutical combination comprises a biguanide and an acetylcholinesterase inhibitor and/or an N-oxide, a hydrate, a pharmaceutically acceptable salt or solvate thereof. The invention is further also directed to the use of said pharmaceutical combination for prevention, stabilization and/or reduction of age-related complaints and/or degenerative complaints; and for improving a measure of life span and/or health span.
Abstract: The present invention relates to coated butyrate and butyrate plus DPP-IV inhibitor tablets. It has been discovered that an inner butyrate core, a first layer neutral polymer which can dissolve in the colon, followed by an outer coating of a composition, which dissolves only in the colon, prevents the interaction of butyrate with these compositions.
Type:
Application
Filed:
February 28, 2020
Publication date:
September 2, 2021
Applicant:
BioKier, Inc.
Inventors:
Jerzy Ryszard Szewczyk, Nicolas D. Kirkland, Troy A. Bartron, JR., Abdul Waseh Basit
Abstract: A method of treating a triterpene-responsive condition, disease or disorder in a subject by administration of an improved triterpene-based composition is provided. An improved triterpene-based composition comprising at least two or at least three triterpenes present at a molar ratio as described herein is also provided.
Type:
Application
Filed:
March 8, 2021
Publication date:
September 2, 2021
Applicant:
PHOENIX BIOTECHNOLOGY, INC.
Inventors:
ROBERT A. NEWMAN, OTIS C. ADDINGTON, DONALD C. LO, LINDA S. KALTENBACH, PEIYING YANG
Abstract: The present disclosure relates to a composition for preventing, alleviating, or treating allodynia caused by anticancer agents, containing cinnamic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The composition of the present disclosure can prevent, alleviate, or treat allodynia by being administered to a subject scheduled to receive anticancer agents or having received anticancer agents.
Type:
Application
Filed:
June 7, 2019
Publication date:
September 2, 2021
Inventors:
Sun Kwang Kim, Zee Hwan Lee, Dae Sik Jang, Woojin Kim, Kyung Jin Lee
Abstract: The invention provides methods, compositions, and medical kits for treating pancreatic cancer using (i) 6,8-bis(benzylsulfanyl)octanoic acid or a pharmaceutically acceptable salt thereof in combination with (ii) gemcitabine or a pharmaceutically acceptable salt thereof, and (iii) nab-paclitaxel.
Abstract: The present invention relates to succinic acid and its derivative(s) of Formula (I), their pharmaceutically acceptable salts, polymorphs, solvates, hydrates, co-crystals, isomers and solvates thereof as an active pharmaceutical ingredient for the treatment of haematological disorder(s). The present invention further relates to compounds of Formula (I), for the treatment of disorders selected from dengue, idiopathic thrombocytopenic purpura (ITP), anaemia and chemotherapy induced myelosuppression. The present invention also relates to use of succinic acid for the treatment of haematological disorder(s), wherein succinic acid is extracted from Papaya leaves. The present invention also provides pharmaceutical compositions comprising succinic acid and its derivative(s) of Formula I and methods of treating haematological disorder(s).
Type:
Application
Filed:
June 22, 2019
Publication date:
September 2, 2021
Inventors:
Himanshu GADGIL, Abir BANERJEE, Arindam CHAKRABORTY, Mazin ADENWALA
Abstract: The present invention provides for a method of improving the release of non-steroidal anti-inflammatory drugs (NSAIDs) from a plaster or bandage comprising an adhesive layer with a pharmaceutically acceptable NSAID together with heparin or a heparinoid. The invention also provides for methods of reducing muscle hyperalgesia in subjects without spontaneous pain.
Abstract: The present invention provides for a method of improving the release of non-steroidal anti-inflammatory drugs (NSAIDs) from a plaster or bandage comprising an adhesive layer with a pharmaceutically acceptable NSAID together with heparin or a heparinoid. The invention also provides for methods of reducing muscle hyperalgesia in subjects without spontaneous pain.
Abstract: Provided herein are fixed-dose combination formulations of a pharmaceutically effective amount of eflornithine together with a pharmaceutically effective amount of sulindac. Also provided are methods of use and of methods of manufacture of these formulations.
Type:
Application
Filed:
March 5, 2021
Publication date:
September 2, 2021
Inventors:
Patrick SHANNON, Roberto Carlos BRAVO GONZĆLEZ, Jean DUCASSOU
Abstract: A self-emulsifying composition contains: 70 to 90% by weight in total of one or more compounds selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 1 to 29% by weight of an emulsifying agent selected from among a polyoxyethylene sorbitan fatty acid ester, a sorbitan fatty acid ester, a glycerin fatty acid ester and a polyoxyl castor oil; and 0.5 to 6% by weight of water when the composition is defined to be 100% by weight as a whole. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.
Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
Abstract: An oral rinse including ionic silver as silver citrate complex and acemannan is useful for the treatment of oral ulceration and oral mucositis. The oral rinse has shown effectiveness against fungal and bacteria species such as Candida species, Staphylococcus aureus and Streptococcus pyogenes.
Type:
Application
Filed:
July 2, 2019
Publication date:
September 2, 2021
Applicant:
CelaCare Technologies, Inc.
Inventors:
Kenneth M. Yates, Celia A. Proctor, Daniel H. Atchley
Abstract: Described herein are compositions of modified binding agents and modified carrier proteins, as well as nanoparticle complexes comprising modified binding agents and modified carrier proteins with optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic.
Type:
Application
Filed:
August 4, 2017
Publication date:
September 2, 2021
Inventors:
Svetomir N. Markovic, Wendy K Nevala, John Thomas Butterfield, Daniel Joseph Knauer
Abstract: Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.
Abstract: In some embodiments of the invention, inventive compounds (e.g., Formula (I), (IA), (II), and (III), and urolithin derivatives) are disclosed. Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.
Type:
Application
Filed:
May 14, 2019
Publication date:
September 2, 2021
Applicants:
University of Louisville Research Foundation, Inc., The Institute for Stem Cell Biology and Regenerative Medicine (InStem)
Abstract: The present invention relates to an oral tablet for delivery of cannabinoids to mucosal surfaces comprising a population of particles and one or more cannabinoids, the population of particles comprising a) directly compressible (DC) sugar alcohol particles and b) non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas.
Abstract: An oral dispersible film composition comprising at least one active ingredient and a film forming agent, as well as a method of manufacture of same. The oral dispersible film composition can be free of gum resin, and can be utilized to administer various active ingredients, including cannabinoids.
Type:
Application
Filed:
July 15, 2019
Publication date:
September 2, 2021
Inventors:
JAMES BENJAMIN MACPHAIL, RINA CARLINI, JAMES LEWIS, EMILY QUINN KAPTEYN
Abstract: The present invention comprises a method of manufacturing a cannabinoid solution including adding to a cannabis source comprising a cannabis distillate or a full spectrum alcohol extracted cannabis oil, adding a PEG, forming a mixture; and adding a PG to the mixture, forming the cannabinoid solution suitable for vaporization and inhalation to administer active cannabis compounds to a person in need thereof.
Type:
Application
Filed:
May 6, 2021
Publication date:
September 2, 2021
Inventors:
Deryl Townsend, Haydn Wilford, Ian Hillier-Brook
Abstract: Provided herein are methods of treating and sensitizing cancer comprising administering a glycolytic inhibitor and an oxidative phosphorylation inhibitor.
Type:
Application
Filed:
March 16, 2021
Publication date:
September 2, 2021
Inventors:
Daniel P. GOLD, Miguel QUINTELA-FANDINO
Abstract: The present disclosure is directed to methods for the treatment of inflammation or pain, particularly methods using compositions containing a compound of formula (I).
Type:
Application
Filed:
March 2, 2021
Publication date:
September 2, 2021
Inventors:
Bill J. Baker, Sofia Kokkaliari, James Leahy, Wayne Caleb Williams
Abstract: Provided herein are multicyclic compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.
Type:
Application
Filed:
November 19, 2020
Publication date:
September 2, 2021
Applicants:
Sunovion Pharmaceuticals Inc., PGI Drug Discovery LLC
Inventors:
Liming SHAO, John Emmerson CAMPBELL, Michael Charles HEWITT, Una CAMPBELL, Taleen G. HANANIA
Abstract: The present invention relates to compositions and methods for the treatment of NAFLD. Specifically, the present invention relates to compositions comprising one or more BCDKH agonists and methods of using the same for the treatment of NAFLD.
Type:
Application
Filed:
June 18, 2019
Publication date:
September 2, 2021
Inventors:
Christopher B. NEWGARD, Phillip WHITE, Thomas GRENIER-LAROUCHE
Abstract: The present invention relates to (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane and pharmaceutical compositions thereof, and methods employing their use in the treatment of conditions affected by monoamine neurotransmitters, including ADHD and substance abuse.
Type:
Application
Filed:
March 12, 2021
Publication date:
September 2, 2021
Inventors:
Anthony Alexander McKinney, Frank Bymaster
Abstract: A method for preparing chlorophyll-containing extract according to an embodiment of the present disclosure may include a chlorophyll extraction step of performing complex supercritical extraction on a plant or microorganism containing chlorophyll. The method effectively removes impurities from raw materials, and the prepared chlorophyll-containing extract has a high content of chlorophyll.
Abstract: Compositions comprising melatonin or derivatives thereof are provided for topical administration to the vaginal and/or rectal epithelium to protect against vaginal and/or rectal radiation injury due to radiotherapy.
Abstract: A method for preventing or treating a tissue injury and/or promoting tissue repair in a subject in need thereof, includes administering to the subject a therapeutically effective amount of an ADH inhibitor, AKR inhibitor, SCoR inhibitor, and/or PKM2 inhibitor.
Abstract: The present disclosure relates to the treatment of agitation or signs of agitation in certain human subjects, including subjects with a neurodegenerative, neuropsychiatric or opioid withdrawal disorder, by administering dexmedetomidine hydrochloride by the intravenous route.
Abstract: Described herein are pharmaceutical compositions including a proton pump inhibitor and an antiparasitic drug. Methods using the compositions are also described.
Type:
Application
Filed:
May 14, 2021
Publication date:
September 2, 2021
Inventors:
David Clayton Sutherland, James Kyle Zorn, Dennis J. Carlo
Abstract: Disclosed are a combination treating prostate cancer, a pharmaceutical composition and a treatment method. The combination includes one of a benzoheterocyclic compound as shown in formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof, a crystalline form thereof, a co-crystal thereof, a stereoisomer thereof, an isotope compound thereof, a metabolite thereof and a prodrug thereof, and an androgen receptor pathway modulator. The combination, the pharmaceutical composition thereof and the treatment method inhibit prostate cancer in a more effective manner.
Type:
Application
Filed:
May 20, 2021
Publication date:
September 2, 2021
Applicant:
KANGPU BIOPHARMACEUTICALS, LTD.
Inventors:
Chuansheng GE, Baisong LIAO, Wen-Cherng LEE
Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2, R3, R4, n and m are as defined herein, which have valuable pharmacological properties, in particular bind to the GPR142 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as type 2 diabetes.
Type:
Application
Filed:
June 28, 2019
Publication date:
September 2, 2021
Inventors:
Armin HECKEL, Robert AUGUSTIN, Sebastian BANDHOLTZ, Sara FRATTINI, Bernd WELLENZOHN
Abstract: Provided herein, inter alia, are methods of treating cancer in a subject, by administering COH29 ((N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4-dihydroxybenzamide)).
Abstract: Disclosed herein are methods of treating conditions, which may be associated with elevated levels of eosinophils and/or basophils, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.
Type:
Application
Filed:
November 18, 2020
Publication date:
September 2, 2021
Inventors:
Michael E. BOZIK, Gregory HEBRANK, Wildon FARWELL, Thomas PETZINGER, JR., Steven DWORETZKY
Abstract: The present invention provides compositions and methods for the treatment of pulmonary hypertension using combination therapy. The combination therapy comprises a compound that increases BMPR2 signaling (BMPR2 activator) in combination with at least one other agent for the treatment of pulmonary hypertension. In certain aspects, the BMPR2 activator can be tacrolimus or a pharmaceutically acceptable solvate, salt, or prodrug thereof.
Type:
Application
Filed:
May 11, 2021
Publication date:
September 2, 2021
Inventors:
Leo Gu, Paul C. Nakagaki, Narinder S. Banait
Abstract: The present invention concerns the use of an alpha-glucosidase glycoprotein processing inhibitor for the treatment or prevention of human coronavirus infections, such as SARS-CoV-2 or SARS-CoV-2 variant infections. Aspects of the invention include methods for treating or preventing coronavirus infection, or a symptom thereof, by administering an alpha-glucosidase glycoprotein processing inhibitor, such as castanospermine, or a pharmaceutically acceptable salt, derivative, or prodrug thereof, to a human subject; methods for inhibiting human coronavirus infection in a human cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing human coronavirus infection.
Type:
Application
Filed:
February 19, 2021
Publication date:
September 2, 2021
Inventors:
ERIC HOLMES, GARY OSTRANDER, GEOFFREY STUART DOW
Abstract: Present invention relates to novel compound of formula (I), their enantiomers, their diastereomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment of bacterial infection.
Abstract: Provision of a granular preparation that contains edoxaban or a pharmacologically acceptable salt thereof, and has the property of being rapidly dissolved or suspended by the addition of water. A granular preparation comprising first granules containing (A) edoxaban or a pharmacologically acceptable salt thereof, (B) a sugar alcohol, and (C) a water-swelling additive, and second granules containing (D) 0.5 to 10% by weight of carmellose sodium with respect to the total weight of the preparation, and (E) 70 to 90% by weight of xylitol or sorbitol with respect to the total weight of the preparation.
Type:
Application
Filed:
June 26, 2019
Publication date:
September 2, 2021
Applicant:
DAIICHI SANKYO COMPANY, LIMITED
Inventors:
Wolfgang SCHMID, Maren KUHLI, Christoph SCHUH
Abstract: The present invention relates to Suprabioavailable oral composition of Pirfenidone or salt thereof when compared with reference product of Pirfenidone capsule [267 mg] and tablet [267 mg and 801 mg] for the treatment of idiopathic pulmonary fibrosis (IPF). The Suprabioavailable oral composition of Pirfenidone or salt thereof provides at least 5% dose reduction which minimizes adverse effects and provides more efficacy with better patient compliance in the treatment of idiopathic pulmonary fibrosis.
Abstract: Provided herein are methods for treating sickle cell disease, comprising administering to a subject 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)-methoxy)benzaldehyde (Compound 1), or a polymorph thereof, in certain dosing regimens.
Type:
Application
Filed:
May 20, 2021
Publication date:
September 2, 2021
Inventors:
Eleanor L. Ramos, Joshua Eli Lehrer-Graiwer, Athiwat Hutchaleelaha, Naveen Bejugam
Abstract: A solid, oral pharmaceutical composition is described. The solid, oral pharmaceutical composition includes methylphenidate or a pharmaceutical salt thereof, wherein an in vivo absorption model of the solid, oral pharmaceutical composition has a function selected from the group consisting of: a single Weibull function, a double Weibull function, and a sigmoid eMax function. A correlation of a plurality of fractions of an in vitro dissolution of the solid, oral pharmaceutical composition with a same plurality of fractions of an in vivo absorption of the solid, oral pharmaceutical composition is non-linear. A method of treating a condition in a subject having a disorder or condition responsive to the administration of methylphenidate is also described. The method includes orally administering to the subject an effective amount of the solid, oral pharmaceutical composition.
Type:
Application
Filed:
May 10, 2021
Publication date:
September 2, 2021
Inventors:
David Lickrish, Beverly J. Incledon, Roberto Gomeni, Joga Gobburu
Abstract: This application relates to methods of diagnosing and treating anorexia nervosa (AN) and binge eating disorder (BED) with a nonselective activator of metabotropic glutamate receptors (mGluRs).
Type:
Application
Filed:
February 12, 2021
Publication date:
September 2, 2021
Applicant:
The Children's Hospital of Philadelphia